Treatment of invasive silent somatotroph pituitary adenoma with Temozolomide.

Report of a case and review of the literature

Ali A. Ghazi, Fabio Rotondo*, Kalman Kovacs, Alireza Amirbaigloo, Luis V. Syro, Hussein Fathalla, Antonio Di Ieva, Michael D. Cusimano

*Corresponding author for this work

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Improved imaging techniques have contributed to increased diagnosis of pituitary tumors. These tumor types can be microadenomas or macroadenomas and can either be functional or non-functional. Atypical or aggressive pituitary adenomas are tumors that rapidly increase in size and may invade into the suprasellar or parasellar regions. They are characterized by a Ki-67 nuclear labeling index greater than 10 %. Management of these tumors is difficult, and many recur after surgery. Temozolomide, a second generation alkylating agent, has been showing promising results in the treatment of these tumors. The patient was a 39-year-old male diagnosed with an invasive silent somatotroph pituitary macroadenoma treated with temozolomide after surgery. We present the case along with the review of the literature of the therapeutic effects of temozolomide in somatotroph macroadenomas.

Original languageEnglish
Article number6
Pages (from-to)135-139
Number of pages5
JournalEndocrine Pathology
Volume26
Issue number2
DOIs
Publication statusPublished - 22 May 2015
Externally publishedYes

Keywords

  • MGMT
  • Pathology
  • Pituitary
  • Somatotroph adenoma
  • Temozolomide

Fingerprint Dive into the research topics of 'Treatment of invasive silent somatotroph pituitary adenoma with Temozolomide. Report of a case and review of the literature'. Together they form a unique fingerprint.

Cite this